Keunchil Park

Keunchil Park is a leading Korean thoracic oncologist who has contributed to clinical development of multiple EGFR and ALK inhibitors for NSCLC, characterizing Korean lung cancer molecular epidemiology and treatment outcomes. His research has examined the prevalence and clinical features of EGFR mutations, ALK rearrangements, ROS1 fusions, and other oncogenic drivers in Korean NSCLC populations, contributing to understanding how molecular epidemiology in East Asian patients shapes treatment algorithm development. He has participated in pivotal trials of second and third generation EGFR TKIs including afatinib and osimertinib and next-generation ALK inhibitors including alectinib and brigatinib in Korean and Asian NSCLC populations. His clinical research has contributed to lung cancer treatment access and guideline development in Korea and the broader Asia-Pacific region.